News

Neurology Advisor6h
Modeyso Approved for H3 K27M-Mutant Diffuse Midline Glioma
The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...
PharmExec4h
FDA Grants Accelerated Approval to Jazz Pharmaceuticals’ Modeyso for H3 K27M-Mutant Diffuse Midline Glioma
Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...
Pharmaceutical Technology on MSN13h
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy
The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) ...
What is glioma? Symptoms explained after death of young actress
Glioma is the most common type of brain cancer in children and younger adults, originating in glial cells and categorized by ...
The American Journal of Managed Care1d
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive ...
Becker's Hospital Review6h
FDA approves brain tumor drug targeting new mutation
The FDA has granted accelerated approval to dordaviprone for the treatment of diffuse midline glioma with an H3 K27M mutation in patients one year old and older with progressive disease following ...